score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable	Guideline			Rearrangement	EML4	Fusion	EML4--ALK			0.0	0.0		Putatively Actionable	Crizotinib	MET inhibition	Targeted therapy	ALK rearrangement, notably with EML4, may suggest sensitivity to Crizotinib as a first or subsequent line of therapy. See NCCN guidelines for more details in the case of resistance to Crizotinib in the presence of ALK rearrangement.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf													0				EML4--ALK Fusion	1.0	KIRP-2Z-A9JJ		
Putatively Actionable	Guideline			Rearrangement	ALK	Fusion	EML4--ALK			0.0	0.0		Putatively Actionable	Crizotinib	MET inhibition	Targeted therapy	ALK rearrangement, notably with EML4, may suggest sensitivity to Crizotinib as a first or subsequent line of therapy. See NCCN guidelines for more details in the case of resistance to Crizotinib in the presence of ALK rearrangement.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf													0				EML4--ALK Fusion	1.0	KIRP-2Z-A9JJ		
Investigate Actionability			Inferential	Aneuploidy	Whole genome doubling																						Investigate Actionability	0.0	WGD was associated with adverse survival pan-cancer in patients with advanced disease and in cancers with heterogeneous clinical outcomes, even following the development of metastasis.	Bielski CM, Zehir A, Penson AV, et al. Genome doubling shapes the evolution and prognosis of advanced cancers Nat Genet. 2018; 50(8):1189-1195.	https://doi.org/10.1038/s41588-018-0165-1	0						KIRP-2Z-A9JJ		
Biologically Relevant				Microsatellite Stability	Supporting variants		MSH3 p.AAA58del (Deletion)																									0				Supporting variants: MSH3 p.AAA58del (Deletion)		KIRP-2Z-A9JJ		
Biologically Relevant				Mutational Signature	COSMIC Signature 6	version 2	0.369																									0				COSMIC Signature (version 2) 6 (37%)		KIRP-2Z-A9JJ		
Biologically Relevant				Mutational Signature	COSMIC Signature 18	version 2	0.201																									0				COSMIC Signature (version 2) 18 (20%)		KIRP-2Z-A9JJ		
